deaths (OS)progression or deaths (PFS)RFS/DFS

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus etoposide plus platin
durvalumab plus tremelimumab plus SoC vs. etoposide plus platin 1 certainty unassessable-17% certainty unassessable-15%-